Xcout Intel
858 Therapeutics, Inc.
858 Therapeutics is a preclinical biotechnology company focused on the discovery and development of novel small molecule therapeutics for cancer treatment. The company concentrates on targeting RNA-modifying enzymes and related pathways to develop oncology drugs that address unmet medical needs. It serves patients with cancer by advancing innovative targeted therapies through the drug discovery pipeline.
Subscribe to see 858 Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
858 Therapeutics, Inc. at a glance
858 Therapeutics, Inc. is a biotechnology company headquartered in United States. Its most recent funding round, Series B, raised $50M in September 2024. Xcout tracks 2 named people at 858 Therapeutics, Inc., including Gretchen Bain (founder).
858 Therapeutics, Inc. leadership
- Gretchen Bainfounder
- Stafford Jeffreyfounder
858 Therapeutics, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $50M | 5 named | |
| SEC Form D filing | $25.2M | — | |
| Series A | $60M | 7 named | |
| SEC Form D filing | $20M | — | |
| SEC Form D filing | $20.1M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
858 Therapeutics, Inc. competitors
A few of 858 Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
EPICS Therapeutics is a clinical-stage biotechnology company headquartered in Gosselies, Belgium, dedicated to drug discovery and development for small molecule drugs. The company pioneers targeted therapies focusing on RNA epigenetic regulation to transform cancer treatment.
Atavistik Bio is a U.S. biotechnology company developing small-molecule medicines by targeting allosteric sites and metabolite-regulated biology, using its chemoproteomics and drug-discovery platform. Its programs are aimed at treating cancer and other serious diseases.
NERx Biosciences, Inc. is a small business enterprise headquartered in Indianapolis, Indiana, dedicated to the discovery and development of targeted therapeutics for cancer.
RayThera is a small molecule drug discovery company founded in August 2023, headquartered in San Diego, CA, United States. Its mission is to develop safer, more effective therapeutics by advancing drug discovery with proven expertise and adaptable approaches. The company focuses on transformative therapies for unmet medical needs.
Bakx Therapeutics, Inc. is a private biotechnology company founded in 2020 and based in New York, United States. The company specializes in pre-clinical oncology drug pipelines and novel therapeutics discovery.
Tessellate Bio is a biotechnology company that develops precision oncology medicines by exploring synthetic lethal interactions beyond homologous recombination deficiency. The company integrates biomarker discovery and companion diagnostics into its research programs to create first-in-class treatments for hard-to-treat cancers.
Get 858 Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about 858 Therapeutics, Inc.? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on 858 Therapeutics, Inc. in Xcout Intel
- 2 named people with titles, LinkedIn and board committees
- 5 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access